China Pharma Holdings: SFDA Approval for Clinical Trials
China Pharma Holdings has received official approval from China's State Food and Drug Administration (SFDA) to enter Phase I and Phase II clinical trials to test the efficacy of its cholesterol-lowering drug, Rosuvastatin.
The company plans to begin the trials in the first half of 2009, and estimates that it will receive a production license by the end of 2010.
- Share this article
- Got more on this story? Email PharmaAsia
- More About
- Clinical Trials
- Rosuvastatin
- cholesterol
- sfda
- approval
